The Balancing Act® Talks Biometric Screening – Improving Health with Corporate Wellness Programs
August 25, 2015
FOR IMMEDIATE RELEASE
Host Olga Villaverde undergoes biometric screening with featured expert Hooper Holmes, Inc. on August 25th Show airing on Lifetime
(POMPANO BEACH, Fla. – PR LOG – August 24, 2015) Award-winning morning show The Balancing Act® will feature one of the hottest names in Biometric Testing and Wellness Programs on Tuesday, August 25, 2015 at 7:30 a.m. (ET/PT) on Lifetime® as part of its “Your Good Health” programming. Tune in as The Balancing Act hosts help jump start the day with lively conversations, and trusted information to empower a woman’s life.
Don’t miss this featured segment taking center stage on The Balancing Act:
- Taking Action to Improve Your Health. Right for You. Right for Your Employer – with Hooper Holmes, Inc.
Healthy employees mean healthier bottom lines. Wellness has become not only a personal priority for many Americans but increasingly a larger part of U.S. companies’ corporate social responsibility and employee focus. A good wellness program can have positive outcomes including: reducing employer healthcare costs, increasing productivity, and decreasing absenteeism. A workplace culture that promotes healthy lifestyles leads to sustainable behavior change, which leads to health improvements, cost savings and improved productivity. Join Wellness and Biometric experts Henry E. Dubois, CEO of Hooper Holmes, a company specializing in biometric screening and corporate wellness solutions, who will discuss what a biometric screening entails and Dr. Neil Gordon, Hooper Holmes Medical Director who performs a biometric screening on our own Host Olga Villaverde during the segment.
To learn more, please visit: http://www.hooperholmes.com
About The Balancing Act®
Entering its 8th season, The Balancing Act continues to empower women in all aspects of their lives. The mission at The Balancing Act is simple – to help today’s modern woman balance it all by bringing them positive solutions to enrich and empower them. Entertaining, educational and trusted by women, viewers can tune in to America’s premier morning show The Balancing Act on weekday mornings Monday through Friday at 7:30 am (ET/PT) on Lifetime television. For additional information or to view a segment visit: www.thebalancingact.com
For more information regarding O2 Media, Branded Entertainment, Product Placement and TV Brand Integration go to: http://o2mediainc.com/Pages/187/Branded-Entertainment
Join the Conversation!
About Hooper Holmes
Hooper Holmes, Inc. is a leading provider of biometric screening services, mobilizing a national network of health professionals to provide quality on-site health screenings, laboratory testing, and sample collection services to wellness and disease management companies, insurance companies, employers, government organizations and academic institutions. In April 2015, Hooper acquired the assets of Accountable Health Solutions, Inc., a leading provider of corporate wellness and health improvement solutions (formerly known as Principal Wellness Company with origins back to 1992, the company became Accountable Health Solutions in 2013). The combination of Hooper and Accountable allows it to offer a full array of wellness products and services that address total population health management for clients interested in more comprehensive, integrated wellness solutions. www.hooperholmes.com
Bringing the best tips from the experts in Atlanta in business, beauty, wealth management, child healthcare, car shopping, and more. Each year, Atlanta’s Women’s Entrepreneurship Initiative selects 15 local female entrepreneurs for a 15-month business training program. We meet women who have grown their companies, created jobs, and broke through the glass ceiling. With some […]
iMCD is the deadliest subtype of Castleman disease. Approximately one third of patients die within five years of diagnosis, and another third die within 10 years if not treated.
There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades.